Humanigen Inc. [NASDAQ: HGEN] gained 54.47% or 7.62 points to close at $21.61 with a heavy trading volume of 88929254 shares. The company report on March 30, 2021 that Humanigen Announces Proposed Public Offering of Five Million Shares of Common Stock.
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumabTM, today announced that it has commenced an underwritten public offering 5,000,000 shares of its common stock. In connection with this offering, Humanigen expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Jefferies, Credit Suisse and Cantor are acting as joint book-running managers for the offering. Bryan, Garnier & Co. is acting as European lead manager for the offering, Oppenheimer & Co. is acting as lead manager for the offering and H.C. Wainwright & Co., National Securities Corporation and Roth Capital Partners are acting as co-managers for the offering.
It opened the trading session at $21.98, the shares rose to $29.20 and dropped to $19.53, the range by which the price of stock traded the whole day. The daily chart for HGEN points out that the company has recorded 121.19% gains over the past six months. However, it is still -535.59% lower than its most recent low trading price.
If we look at the average trading volume of 997.30K shares, HGEN reached to a volume of 88929254 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Humanigen Inc. [HGEN]:
JP Morgan have made an estimate for Humanigen Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 23, 2021. While these analysts kept the previous recommendation, National Securities raised their target price to Buy. The new note on the price target was released on December 23, 2020, representing the official price target for Humanigen Inc. stock. Previously, the target price had yet another raise to $27, while Jefferies analysts kept a Buy rating on HGEN stock.
The Average True Range (ATR) for Humanigen Inc. is set at 2.92, with the Price to Sales ratio for HGEN stock in the period of the last 12 months amounting to 3788.95. The Price to Book ratio for the last quarter was 24.56, with the Price to Cash per share for the same quarter was set at 1.29.
Trading performance analysis for HGEN stock
Humanigen Inc. [HGEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 37.29. With this latest performance, HGEN shares gained by 16.25% in over the last four-week period, additionally plugging by 121.19% over the last 6 months – not to mention a rise of 243.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HGEN stock in for the last two-week period is set at 63.33, with the RSI for the last a single of trading hit 69.71, and the three-weeks RSI is set at 59.78 for Humanigen Inc. [HGEN]. The present Moving Average for the last 50 days of trading for this stock 18.33, while it was recorded at 15.31 for the last single week of trading, and 16.16 for the last 200 days.
Humanigen Inc. [HGEN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Humanigen Inc. [HGEN] shares currently have an operating margin of -28268.59. Humanigen Inc.’s Net Margin is presently recorded at -28697.12.
Return on Total Capital for HGEN is now -467.72, given the latest momentum, and Return on Invested Capital for the company is -551.43. Return on Equity for this stock declined to -573.45, with Return on Assets sitting at -260.18.
Reflecting on the efficiency of the workforce at the company, Humanigen Inc. [HGEN] managed to generate an average of -$8,953,500 per employee.Humanigen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.30 and a Current Ratio set at 3.30.
Humanigen Inc. [HGEN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HGEN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Humanigen Inc. go to 12.50%.
An analysis of insider ownership at Humanigen Inc. [HGEN]
There are presently around $195 million, or 24.70% of HGEN stock, in the hands of institutional investors. The top three institutional holders of HGEN stocks are: VALIANT CAPITAL MANAGEMENT, L.P. with ownership of 7,074,220, which is approximately 0% of the company’s market cap and around 40.28% of the total institutional ownership; VANGUARD GROUP INC, holding 1,615,710 shares of the stock with an approximate value of $22.6 million in HGEN stocks shares; and THINK INVESTMENTS LP, currently with $18.72 million in HGEN stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Humanigen Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 30 institutional holders increased their position in Humanigen Inc. [NASDAQ:HGEN] by around 3,930,070 shares. Additionally, 15 investors decreased positions by around 4,766,641 shares, while 5 investors held positions by with 5,218,977 shares. The mentioned changes placed institutional holdings at 13,915,688 shares, according to the latest SEC report filing. HGEN stock had 24 new institutional investments in for a total of 3,701,357 shares, while 11 institutional investors sold positions of 3,970,304 shares during the same period.